Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients.

Kaserer K, Scheuba C, Neuhold N, Weinhäusel A, Haas OA, Vierhapper H, Niederle B.

Am J Surg Pathol. 2001 Oct;25(10):1245-51.

PMID:
11688458
2.

Primary hereditary medullary thyroid carcinoma--C-cell morphology and correlation with preoperative calcitonin levels.

Hinze R, Holzhausen HJ, Gimm O, Dralle H, Rath FW.

Virchows Arch. 1998 Sep;433(3):203-8.

PMID:
9769122
3.

Recommendations for reporting C cell pathology of the thyroid.

Kaserer K, Scheuba C, Neuhold N, Weinhäusel A, Vierhapper H, Niederle B.

Wien Klin Wochenschr. 2002 Apr 15;114(7):274-8.

PMID:
12089863
4.

C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin.

Kaserer K, Scheuba C, Neuhold N, Weinhäusel A, Vierhapper H, Haas OA, Niederle B.

Am J Surg Pathol. 1998 Jun;22(6):722-8.

PMID:
9630179
5.

Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma.

Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Kuma S, Kuma K, Futami H, Yamaguchi K.

World J Surg. 2000 Nov;24(11):1367-72.

PMID:
11038208
6.

[Preventive radical surgery of C-cell carcinoma in MEN-II syndrome based on genetic screening].

Röher HD, Simon D, Goretzki PE, Höppner W, Lederbogen S, Seppel T.

Chirurg. 1995 Dec;66(12):1196-202. German.

PMID:
8582162
7.

C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.

Guyétant S, Josselin N, Savagner F, Rohmer V, Michalak S, Saint-André JP.

Mod Pathol. 2003 Aug;16(8):756-63.

8.

Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.

Sanso GE, Domene HM, Garcia R, Pusiol E, de M, Roque M, Ring A, Perinetti H, Elsner B, Iorcansky S, Barontini M.

Cancer. 2002 Jan 15;94(2):323-30.

9.

Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.

Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler ML, Morange S, Conte-Devolx B; French Calcitonin Tumors Group (GETC)..

J Clin Endocrinol Metab. 2001 Aug;86(8):3746-53.

PMID:
11502806
10.

Importance of early screening and prophylactic thyroidectomy in asymptomatic nonindex RET germline carriers.

Ukkat J, Lorenz K, Hinze R, Thomusch O, Dralle H.

World J Surg. 2001 Jun;25(6):713-7.

PMID:
11376404
11.

Inherited medullary microcarcinoma of the thyroid: a study of 11 cases.

Krueger JE, Maitra A, Albores-Saavedra J.

Am J Surg Pathol. 2000 Jun;24(6):853-8.

PMID:
10843288
12.

Histopathologic and clinical features of medullary microcarcinoma and C-cell hyperplasia in prophylactic thyroidectomies for medullary carcinoma: a study of 42 cases.

Etit D, Faquin WC, Gaz R, Randolph G, DeLellis RA, Pilch BZ.

Arch Pathol Lab Med. 2008 Nov;132(11):1767-73. doi: 10.1043/1543-2165-132.11.1767.

PMID:
18976013
13.

Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests.

Scheuba C, Kaserer K, Weinhäusl A, Pandev R, Kaider A, Passler C, Prager G, Vierhapper H, Haas OA, Niederle B.

Surgery. 1999 Dec;126(6):1089-95; discussion 1096.

PMID:
10598192
14.

Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.

Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, Delbridge L, Eng C, Robinson BG.

Clin Endocrinol (Oxf). 1996 Mar;44(3):249-57.

PMID:
8729519
15.

Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.

González-Yebra B, Medrano ME, Mantilla A, Palma V, Colin C, Hernández DM, Tapia J, Dawson B, Salcedo M.

Endocr Pathol. 2003 Spring;14(1):71-80.

PMID:
12746565
16.

Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome?

Hansen HS, Torring H, Godballe C, Jäger AC, Nielsen FC.

Cancer. 2000 Aug 15;89(4):863-7.

PMID:
10951350
17.

Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations.

Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y, Nakano K, Kuma K, Futami H, Yamaguchi K.

World J Surg. 2002 Aug;26(8):1023-8. Epub 2002 May 21.

PMID:
12016484
18.

Regulation of proliferation and apoptosis in sporadic and hereditary medullary thyroid carcinomas and their putative precursor lesions.

Hinze R, Gimm O, Taubert H, Bauer G, Dralle H, Holzhausen HJ, Rath FW.

Virchows Arch. 2000 Sep;437(3):256-63.

PMID:
11037345
19.

Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634.

Gimm O, Ukkat J, Niederle BE, Weber T, Thanh PN, Brauckhoff M, Niederle B, Dralle H.

World J Surg. 2004 Dec;28(12):1312-6. Epub 2004 Nov 4.

PMID:
15517481
20.

Tenascin C in medullary thyroid microcarcinoma and C-cell hyperplasia.

Koperek O, Prinz A, Scheuba C, Niederle B, Kaserer K.

Virchows Arch. 2009 Jul;455(1):43-8. doi: 10.1007/s00428-009-0786-y. Epub 2009 May 30.

PMID:
19484261

Supplemental Content

Support Center